The soaring continues: The papers from Biontech continue their record rally. In terms of market value, the company is at the level of the top Dax groups. The quarterly figures are to be published in a few days.
The soaring mRNA vaccine stocks continue to know no bounds. The papers of the German company Biontech shot up on Wednesday in New York by almost a quarter to 433.90 dollars and continued their record rally.
A good half an hour before the end of trading, they gained 14 percent to a good $ 401. The market value amounts to more than 100 billion dollars (84.2 billion euros). The company plans to publish quarterly figures in a few days.
For comparison: Due to the current development, Biontech is moving in terms of market value in the spheres of top Dax companies such as Deutsche Telekom or Daimler (). The Biontech share is traded on the Nasdaq in New York.
As the “New York Times” reported on Wednesday night, citing people familiar with the matter, the US health authority FDA intends to give the corona vaccine, which is marketed jointly with Pfizer, final approval in September. So far it has only been an emergency approval.
Biontech partner Pfizer is also growing
The Pfizer shares also had no stopping in New York recently, they are making great strides towards their previous record from the time before the turn of the millennium. On Wednesday, however, they took a break for the time being and finally gave way by 0.7 percent. By the time it reached $ 47.45 in 1999, not much is missing.
The tailwind extends to Moderna shares, which also continued their record rally in the US on Wednesday. The paper had gone out of trading the day before, with a plus of more than eleven percent.
Jane Stock is a technology author, who has written for 24 Hours World. She writes about the latest in technology news and trends, and is always on the lookout for new and innovative ways to improve his audience’s experience.
